(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/30448 A1

(51) International Patent Classification[7]: A61P 35/00, A61K 47/42, 31/335

(21) International Application Number: PCT/US00/29633

(22) International Filing Date: 27 October 2000 (27.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/162,310 27 October 1999 (27.10.1999) US

(71) Applicant *(for all designated States except US)*: **BAKER NORTON PHARMACEUTICALS, INC.** [US/US]; 4400 Biscayne Boulevard, Miami, FL 33137 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BRODOR, Samuel** [US/US]; 45 West Gude Drive, Rockville, MD 20850 (US). **DUCHIN, Kenneth** [US/US]; 2679 Cypress Lane, Weston, FL 33332 (US). **SELIM, Sami** [US/US]; 17 Camellia, Irvine, CA 92620 (US).

(74) Agent: **LEVI-MINZI, Simona, A.**; Baker Norton Pharmaceuticals, Inc., 4400 Biscayne Boulevard, Miami, FL 33137 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*
— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

[Continued on next page]

(54) **Title:** METHOD AND COMPOSITIONS FOR ADMINISTERING TAXANES ORALLY TO HUMAN PATIENTS

TOXICITY: SINGLE DOSE ESCALATION

mg/m2	N	leuko				ANC			
		1	2	3	4	1	2	3	4
60	22	2	–	–	–	–	–	–	–
120	3	1	–	1	1	–	–	–	2
180	6	–	1	1	–	–	–	1	1
210	4	–	2	–	–	1	–	1	1
250	4	1	–	1	–	–	–	1	–
300	7	–	–	–	–	1	–	–	–
360	5	–	–	–	–	–	–	–	–

(57) **Abstract:** Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.

WO 01/30448 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.